



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/32, A01N 63/02	A2	(11) International Publication Number: WO 91/14778 (43) International Publication Date: 3 October 1991 (03.10.91)
(21) International Application Number: PCT/US91/01786 (22) International Filing Date: 18 March 1991 (18.03.91) (30) Priority data: 496,568 20 March 1990 (20.03.90) US (71) Applicant: ECOGEN INC. [US/US]; 2005 Cabot Boulevard West, Langhorne, PA 19047-1810 (US). (72) Inventors: DONOVAN, William, P. ; 36 Calicobush Road, Levittown, PA 19057 (US). RUPAR, Mark, J. ; 2225-C Prior Road, Wilmington, DE 19809 (US). SLANEY, Annette, C. ; 4 Dunmoor Court South, Hamilton Square, NJ 08690 (US). JOHNSON, Timothy, B. ; 142 E. Highland Avenue, Langhorne, PA 19047 (US).		(74) Agents: NADEL, Alan, S.; Panitch, Schwarze, Jacobs & Nadel, 1601 Market Street, 36th Floor, Philadelphia, PA 19103 (US) et al. (81) Designated States: AT (European patent), AU, BE (European patent), BR, CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU. Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: <i>BACILLUS THURINGIENSIS cryIIIc</i> GENE AND PROTEIN TOXIC TO COLEOPTERAN INSECTS (57) Abstract A purified and isolated <i>cryIIIc</i> -type gene was obtained from a novel <i>B.t.</i> strain. The gene has a nucleotide base sequence coding for the amino acid sequence illustrated in Figure 1. The 74.4 kDa protein produced by this gene is an irregularly shaped crystal that is toxic to coleopteran insects, including Colorado potato beetle and insects of the genus <i>Diabrotica</i> .		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

- 1 -

5 BACILLUS THURINGIENSIS cryIIIC GENE AND
 PROTEIN TOXIC TO COLEOPTERAN INSECTS

Field of the Invention

 The present invention relates to a gene
isolated from Bacillus thuringiensis (hereinafter
"B.t.") encoding an insecticidal crystal protein
10 designated CryIIIC, as well as insecticidal
compositions containing the protein and plants
transformed with the gene. The insecticidal
compositions and transformed plants are toxic to
insects of the order Coleoptera, and are
15 particularly toxic to insects of the genus
Diabrotica.

Background of the Invention

B.t. is a gram-positive soil bacterium
that produces crystal proteins during sporulation
20 which are specifically toxic to certain orders and
species of insects. Many different strains of B.t.
have been shown to produce insecticidal crystal
proteins. Compositions including B.t. strains
which produce insecticidal proteins have been
25 commercially available and used as environmentally
acceptable insecticides because they are quite
toxic to the specific target insect, but are
harmless to plants and other non-targeted
organisms.

- 2 -

A number of genes encoding crystal proteins have been cloned from several strains of B.t. A good overview is set forth in H. Hofte et al., Microbiol. Rev., 53, pp. 242-255 (1989).

5 While this reference is not prior art with respect to the present invention, it provides a good overview of the genes and proteins obtained from B.t. and their uses, adopts a nomenclature and classification scheme for B.t. genes and proteins,
10 and has an extensive bibliography.

The B.t. crystal protein is active in the insect only after ingestion. After ingestion by an insect, the alkaline pH and proteolytic enzymes in the mid-gut solubilize the crystal allowing the
15 release of the toxic components. These toxic components disrupt the mid-gut cells causing the insect to cease feeding and, eventually, to die. In fact, B.t. has proven to be an effective and environmentally safe insecticide in dealing with
20 various insect pests.

As noted by Hofte et al., the majority of insecticidal B.t. strains are active against insects of the order Lepidoptera, i.e., caterpillar insects. Other B.t. strains are insecticidally
25 active against insects of the order Diptera, i.e., flies and mosquitoes, or against both lepidopteran and dipteran insects. In recent years, a few B.t. strains have been reported as producing crystal protein that is insecticidal to insects of the
30 order Coleoptera, i.e., beetles.

The first isolation of a coleopteran-toxic B.t. strain is reported by A. Krieg et al., in Z. angew. Ent., 96, pp. 500-508 (1983); see

- 3 -

- also A. Krieg et al., Anz. Schaedlingskde, Pflanzenschutz, Umweltschutz, 57, pp. 145-150 (1984) and U.S. Patent 4,766,203, issued August 23, 1988 of A. Krieg et al. The strain, designated
- 5 B.t. var. tenebrionis, is reported to be toxic to larvae of the coleopteran insects Agelastica alni (blue alder leaf beetle) and Leptinotarsa decemlineata (Colorado potato beetle). B.t. tenebrionis makes an insecticidal crystal protein
- 10 reported to be about 65-70 kilodaltons (kDa) (U.S. Patent 4,766,203; see also K. Bernhard, FEMS Microbiol. Lett. 33, pp. 261-265 (1986).
- V. Sekar et al., Proc. Natl. Acad. Sci. USA, 84, pp. 7036-7040 (1987), report the cloning
- 15 and characterization of the gene for the coleopteran-toxic crystal protein of B.t. tenebrionis. The size of the protein, as deduced from the sequence of the gene, was 73 kDa, but the isolated protein contained primarily a 65 kDa
- 20 component. Hofte et al., Nucleic Acids Research, 15, p. 7183 (1987), also report the DNA sequence for the cloned gene from B.t. tenebrionis, and the sequence of the gene is identical to that reported by Sekar et al. (1987).
- 25 McPherson et al., Bio/Technology, 6, pp. 61-66 (1988), disclose the DNA sequence for the cloned insect control gene from B.t. tenebrionis, and the sequence is identical to that reported by Sekar et al. (1987). E. coli cells and Pseudomonas
- 30 fluorescens cells harboring the cloned gene were found to be toxic to Colorado potato beetle larvae.

- 4 -

A coleopteran-toxic strain, designated B.t. var. san diego, is reported by C. Herrnstadt et al., Bio/Technology, 4, pp. 305-308 (1986), to produce a 64 kDa crystal protein that was toxic to various coleopteran insects: strong toxicity to Pyrrhalta luteola (elm leaf beetle); moderate toxicity to Anthonomus grandis (boll weevil), Leptinotarsa decemlineata (Colorado potato beetle), Otiorhynchus sulcatus (black vine weevil), Tenebrio molitor (yellow mealworm) and Haltica tombacina; and weak toxicity to Diabrotica undecimpunctata undecimpunctata (western spotted cucumber beetle).

The DNA sequence of the cloned coleopteran toxin gene of B.t. san diego is reported in C. Herrnstadt et al., Gene, 57, pp. 37-46 (1987); see also U.S. Patent 4,771,131, issued September 13, 1988, of Herrnstadt et al. The sequence of the toxin gene of B.t. san diego is identical to that reported by Sekar et al. (1987) for the cloned coleopteran toxin gene of B.t. tenebrionis.

A. Krieg et al., J. Appl. Ent., 104, pp. 417-424 (1987), report that the strain B.t. san diego is identical to the B.t. tenebrionis strain, based on various diagnostic tests.

Another new B.t. strain, designated EG2158, is reported by W. P. Donovan et al., Mol. Gen. Genet., 214 pp. 365-372 (1988) to produce a 73 kDa crystal protein that is insecticidal to coleopteran insects. The toxin-encoding gene from B.t. strain EG2158 was cloned and sequenced, and its sequence is identical to that reported by Sekar et al. (1987) for the cloned B.t. tenebrionis

- 5 -

coleopteran toxin gene. This coleopteran toxin gene is referred to as the cryIIIA gene by Höfte et al., Microbiol. Rev., 53, pp. 242-255 (1989).

U.S. Patent 4,797,279, issued January 10, 1989, of D. Karamata et al., discloses a hybrid B.t. microorganism containing a plasmid from B.t. kurstaki with a lepidopteran toxin gene and a plasmid from B.t. tenebrionis with a coleopteran toxin gene. The hybrid B.t. produces crystal proteins characteristic of those made by B.t. kurstaki, as well as of B.t. tenebrionis.

European Patent Application Publication No. 0 303 379, published February 15, 1989, of Mycogen Corporation, discloses a novel B.t. isolate identified as B.t. MT 104 which has insecticidal activity against both coleopteran and lepidopteran insects.

European Patent Application Publication No. 0 318 143, published May 31, 1989, of Lubrizol Genetics, Inc., discloses the cloning, characterization and selective expression of the intact partially modified gene from B.t. tenebrionis, and the transfer of the cloned gene into a host microorganism rendering the microorganism able to produce a protein having toxicity to coleopteran insects. Insect bioassay data for B.t. san diego reproduced from Herrnstadt et al., Bio/Technology, 4, pp. 305-308 (1986) discussed above, is summarized. The summary also includes data for B.t. tenebrionis, from another source; B.t. tenebrionis is reported to exhibit strong toxicity to Colorado potato beetle, moderate

- 6 -

toxicity to western corn rootworm (Diabrotica virgifera virgifera) and weak toxicity to southern corn rootworm (Diabrotica undecimpunctata).

European Patent Application Publication

- 5 No. 0 324 254, published July 19, 1989, of Imperial Chemical Industries PLC, discloses a novel B.t. strain identified as A30 which has insecticidal activity against coleopteran insects.

European Patent Application Publication

- 10 No. 0 328 383, published August 16, 1989, of Mycogen Corporation, discloses a novel B.t. microorganism identified as B.t. PS40D1 which has insecticidal activity against coleopteran insects.

European Patent Application Publication

- 15 No. 0 330 342, published August 30, 1989, of Mycogen Corporation, discloses a novel B.t. microorganism identified as B.t. PS86B1 which has insecticidal activity against coleopteran insects.

- 20 These latter four publications are not prior art with respect to the present invention.

- B.t. tenebrionis, first reported by A. Krieg et al., was discovered in or near Darmstadt, Germany and it is believed that B.t. san diego, reported by Herrnstadt et al., was obtained
25 from a location in or near San Diego, California. B.t. strain EG2158, reported by Donovan et al., was isolated from a sample of crop dust from Kansas. Thus, various B.t. strains that have been isolated
30 from several widely separated geographical locations all contained an apparently identical coleopteran toxin gene, the cryIIIA gene.

- 7 -

There appear to be no reports in the literature of any new coleopteran toxin B.t. genes other than the unique B.t. gene first discovered in B.t. tenebrionis over seven years ago.

5 Moreover, even among the various B.t. strains that have been reported as having crystal proteins insecticidally active against coleopteran insects, none has been shown to have significant toxicity to the larvae and adults of the insect
10 genus Diabrotica (corn rootworm), which includes the western corn rootworm (Diabrotica virgifera virgifera), the southern corn rootworm (Diabrotica undecimpunctata howardi) and the northern corn rootworm (Diabrotica barberi). The cryIIIC gene of
15 the present invention expresses protein toxin having quantifiable insecticidal activity against the Diabrotica insects, among other coleopteran insects.

Summary of the Invention

20 One aspect of the present invention relates to a purified and isolated coleopteran toxin gene having a nucleotide base sequence coding for the amino acid sequence illustrated in Figure 1 and hereinafter designated as the cryIIIC gene.
25 The cryIIIC gene has a coding region extending from nucleotide bases 14 to 1972 shown in Figure 1.

 Another aspect of the present invention relates to the insecticidal protein produced by the cryIIIC gene. The CryIIIC protein has the amino
30 acid sequence, as deduced from the nucleotide sequence of the cryIIIC gene from bases 14 to 1972, that is shown in Figure 1. The protein exhibits

- 8 -

insecticidal activity against insects of the order Coleoptera, in particular, Colorado potato beetle and insects of the genus Diabrotica.

Still another aspect of the present invention relates to a biologically pure culture of a B.t. bacterium deposited with the NRRL having Accession No. NRRL B-18533 and being designated as B.t. strain EG4961. B.t. strain EG4961 carries the cryIIIC gene and produces the insecticidal CryIIIC protein. Biologically pure cultures of other B.t. bacteria carrying the cryIIIC gene are also within the scope of this invention.

Yet another aspect of this invention relates to insecticidal compositions containing, in combination with an agriculturally acceptable carrier, either the CryIIIC protein or fermentation cultures of a B.t. strain which has produced the CryIIIC protein.

The invention also includes a method of controlling coleopteran insects by applying to a host plant for such insects an insecticidally effective amount of the CryIIIC protein or of a fermentation culture of a B.t. strain that has made the CryIIIC protein. The method is applicable to a variety of coleopteran insects, including Colorado potato beetle, elm leaf beetle, imported willow leaf beetle and corn rootworm.

Still another aspect of the present invention relates to a recombinant plasmid containing the cryIIIC gene, a biologically pure culture of a bacterium transformed with such

- 9 -

recombinant plasmid, the bacterium preferably being B.t., as well as a plant transformed with the cryIIIC gene.

5 A further aspect of the present invention relates to a method of enhancing the insecticidal activity against coleopteran insects of an insecticidal composition containing a coleopteran-toxic protein, where the method comprises adding to, or incorporating into, the composition
10 containing a CryIII protein a CryI protein in an amount effective to enhance the insecticidal activity of the composition. Insecticidal compositions containing the CryIIIC protein and a CryI protein exhibit enhanced insecticidal activity
15 is against insects of the order Coleoptera, particularly Colorado potato beetle and corn rootworm.

Brief Description of the Drawings

Figure 1 comprises Figures 1-1 through
20 1-3 and shows the nucleotide base sequence of the cryIIIC gene and the deduced amino acid sequence of the CryIIIC protein. The putative ribosome binding site (RBS) is indicated. HindIII and BamHI restriction sites are also indicated.

25 Figure 2 is a photograph of an ethidium bromide stained agarose gel containing size fractionated native plasmids of B.t. strains EG2158, EG2838 and EG4961. The numbers to the right of Figure 2 indicate the approximate sizes,
30 in megadaltons (MDa), of the plasmids of B.t. strain EG4961.

- 10 -

Figure 3 is a photograph of an autoradiogram made by transferring the plasmids shown in Figure 2 to a nitrocellulose filter, hybridizing the filter with a radioactively labeled 2.4 kilobase (kb) cryIIIB probe, and exposing the filter to X-ray film. The number to the right of Figure 3 indicates the size, in MDa, of the plasmid of B.t. strain EG4961 that hybridizes to the cryIIIB probe. The letter "f" to the right of Figure 3 indicates the fragments that result from the breakdown of the cryIIIB-hybridizing plasmid.

Figure 4 is a photograph of an ethidium bromide stained agarose gel containing DNA from B.t. strains EG2158, EG2838 and EG4961 that has been digested with HindIII plus EcoRI and size fractionated by electrophoresis. The lane labeled "stnd" is a size standard.

Figure 5 is a photograph of an autoradiogram made by transferring the DNA fragments of Figure 4 to a nitrocellulose filter, hybridizing the filter with the radioactively labeled 2.4 kb cryIIIB probe, and exposing the filter to X-ray film. The numbers to the right of Figure 5 indicate the sizes, in kb, of B.t. strain EG4961 restriction fragments that hybridize to the cryIIIB probe. The lane labeled "stnd" is a size standard.

Figure 6 is a photograph of a Coomassie stained sodium dodecyl sulfate ("SDS") polyacrylamide gel showing crystal proteins solubilized from B.t. strains EG2158, EG2838 and

- 11 -

EG4961. The numbers to the right of Figure 6 indicate the approximate sizes in kDa of the crystal proteins produced by B.t. strain EG4961.

Figure 7 shows a restriction map of
5 plasmid pEG258. The location and orientation of the cryIIIC gene is indicated by an arrow. A gene designated the cryX gene is located within the region indicated by the dotted line. Asp stands for Asp718, Bam stands for BamHI, H3 stands for
10 HindIII and P stands for PstI restriction enzymes. A one kb scale marker is also illustrated.

Figure 8, aligned with and based on the same scale as Figure 7, shows a restriction map of plasmid pEG260 containing an 8.3 kb fragment of DNA
15 from B.t. strain EG4961 where the cryIIIC gene is indicated by an arrow and the cryX gene is located within the region indicated by the dotted line. In addition to the abbreviations for the restriction enzymes set forth above regarding Figure 7,
20 (RV/Asp) stands for the fusion of EcoRV and Asp718 restrictions sites, and (RV/Pst) stands for the fusion of EcoRV and PstI restriction sites.

Figure 9, aligned with and based on the same scale as Figure 7, shows a restriction map of
25 plasmid pEG269 containing the cryIIIC gene as indicated by an arrow, as part of a fragment of DNA from recombinant E. coli strain EG7233. The abbreviations used with regard to pEG258 illustrated in Figure 7 are applicable to this
30 figure. In addition, Sph stands for the SphI restriction site, and S3A/Bam stands for the fusion of SauIIIA and BamHI restriction sites.

- 12 -

Figure 10 is a photograph of a Coomassie stained SDS-polyacrylamide gel. The gel shows protein bands synthesized by the following bacterial strains: E. coli strain

5 EG7221(pUC18/Cry⁻); E. coli strain EG7218(pEG258/cryIIIC⁺ cryX⁺); B.t. strain EG7211(pEG220/Cry⁻); B.t. strain EG4961(cryIIIC⁺ cryX⁺); B.t. strain EG7231(pEG269/cryIIIC⁺ cryX⁻); and B.t. strain EG7220(pEG260/cryIIIC⁺ cryX⁺). The

10 numbers to the right of the gel indicate approximate sizes, in kDa, of the crystal proteins produced by these strains.

Detailed Description of the Preferred Embodiments

The isolation and purification of the

15 cryIIIC gene and the coleopteran-toxic CryIIIC crystal protein and the characterization of the new B.t. strain EG4961 which produces the CryIIIC protein are described at length in the Examples. The utility of B.t. strain EG4961 and of the

20 CryIIIC crystal protein in insecticidal compositions and methods is also illustrated in the Examples.

The Examples also illustrate the synergistic enhancement of the insecticidal

25 activity of CryIII protein by the addition of a CryI protein. Thus, insecticidal compositions having a combination of both CryIII and CryI proteins provide enhanced insecticidal activity, particularly with respect to both larvae and adult

30 Colorado potato beetle and southern corn rootworm, as well as other insects.

- 13 -

The cryIII-type gene of this invention, the cryIIIC gene, has the nucleotide base sequence shown in Figure 1. The coding region of the cryIIIC gene extends from nucleotide base position 14 to position 1972 shown in Figure 1.

A comparison of the nucleotide base pairs of the cryIIIC gene coding region with the corresponding coding region of the prior art cryIIIA gene indicates significant differences between the two genes. The cryIIIC gene is only 75% homologous (positionally identical) with the cryIIIA gene.

A comparison of the nucleotide base pairs of the cryIIIC gene coding region with the corresponding coding region of the cryIIIB gene obtained from recently discovered B.t. strain EG2838 (NRRL Accession No. B-18603) indicates that the cryIIIC gene is 96% homologous (positionally identical) with the cryIIIB gene.

The CryIII-type protein of this invention, the CryIIIC protein, that is encoded by the cryIIIC gene, has the amino acid sequence shown in Figure 1. In this disclosure, references to the CryIIIC "protein" are synonymous with its description as a "crystal protein", "protein toxin", "insecticidal protein" or the like, unless the context indicates otherwise. The size of the CryIIIC protein, as deduced from the DNA sequence of the cryIIIC gene, is 74.4 kDa.

- 14 -

The size of the CryIIIB protein, as deduced from the sequence of the cryIIIB gene, is 74.2 kDa. The prior art CryIIIA protein, encoded by the cryIIIA gene, has a deduced size of 73.1 kDa.

Despite the apparent size similarity, comparison of the amino acid sequence of the CryIIIC protein with that of the prior art CryIIIA protein shows significant differences between the two. The CryIIIC protein is only 69% homologous (positionally identical amino acids) with the CryIIIA protein. The CryIIIC protein is 94% homologous with the CryIIIB protein. Nevertheless, despite the apparent homology of the CryIIIC and CryIIIB proteins, the CryIIIC protein has been shown to be a different protein than the CryIIIB protein, based on its significantly improved insecticidal activity compared to the CryIIIB protein with respect to insects of the order Coleoptera and in particular, insects of the genus Diabrotica. The CryIIIC protein is the first B.t. protein to exhibit quantifiable insecticidal activity against corn rootworms.

The present invention is intended to cover mutants and recombinant or genetically engineered derivatives of the cryIIIC gene that yield a coleopteran-toxic protein with essentially the same properties as the CryIIIC protein.

The cryIIIC gene is also useful as a DNA hybridization probe, for discovering similar or closely related cryIII-type genes in other B.t. strains. The cryIIIC gene, or portions or derivatives thereof, can be labeled for use as a

- 15 -

hybridization probe, e.g., with a radioactive label, using conventional procedures. The labeled DNA hybridization probe may then be used in the manner described in the Examples.

5 The cryIIIC gene and the corresponding insecticidal CryIIIC protein were first identified in B.t. strain EG4961, a novel B.t. strain. The characteristics of B.t. strain EG4961 are more fully described in the Examples. Comparison of the
10 plasmid arrays and other strain characteristics of B.t. strain EG4961 with those of the recently discovered B.t. strain EG2838 and those of the prior art B.t. strain EG2158 demonstrates that these three coleopteran-toxic B.t. strains are
15 distinctly different.

 The cryIIIC gene may be introduced into a variety of microorganism hosts, using procedures well known to those skilled in the art for transforming suitable hosts under conditions which
20 allow for stable maintenance and expression of the cloned cryIIIC gene. Suitable hosts that allow the cryIIIC gene to be expressed and the CryIIIC protein to be produced include Bacillus
thuringiensis and other Bacillus species such as B.
25 subtilis or B. megaterium. It should be evident that genetically altered or engineered microorganisms containing the cryIIIC gene can also contain other toxin genes present in the same microorganism and that these genes could
30 concurrently produce insecticidal crystal proteins different from the CryIIIC protein.

- 16 -

The Bacillus strains described in this disclosure may be cultured using conventional growth media and standard fermentation techniques. The B.t. strains harboring the cryIIIC gene may be
5 fermented, as described in the Examples, until the cultured B.t. cells reach the stage of their growth cycle when CryIIIC crystal protein is formed. For sporogenous B.t. strains, fermentation is typically continued through the sporulation stage when the
10 CryIIIC crystal protein is formed along with spores. The B.t. fermentation culture is then typically harvested by centrifugation, filtration or the like to separate fermentation culture solids, containing the CryIIIC crystal protein,
15 from the aqueous broth portion of the culture.

The B.t. strains exemplified in this disclosure are sporulating varieties (spore forming or sporogenous strains) but the cryIIIC gene also has utility in asporogenous Bacillus strains, i.e.,
20 strains that produce the crystal protein without production of spores. It should be understood that references to "fermentation cultures" of B.t. strains (containing the cryIIIC gene) in this disclosure are intended to cover sporulated B.t.
25 cultures, i.e., B.t. cultures containing the CryIIIC crystal protein and spores, and sporogenous Bacillus strains that have produced crystal protein during the vegetative stage, as well as asporogenous Bacillus strains containing the
30 cryIIIC gene in which the culture has reached the growth stage where crystal protein is actually produced.

- 17 -

The separated fermentation solids are primarily CryIIIC crystal protein and B.t. spores, along with some cell debris, some intact cells, and residual fermentation medium solids. If desired, the crystal protein may be separated from the other recovered solids via conventional methods, e.g., sucrose density gradient fractionation. Highly purified CryIIIC protein may be obtained by solubilizing the recovered crystal protein and then reprecipitating the protein from solution.

The CryIIIC protein, as noted earlier, is a potent insecticidal compound against coleopteran insects, such as the Colorado potato beetle, elm leaf beetle, imported willow leaf beetle, and the like. The CryIIIC protein, in contrast to the CryIIIA and CryIIIB proteins, exhibits measurable insecticidal activity against Diabrotica insects, e.g., corn rootworms, which have been relatively unaffected by other coleopteran-toxic B.t. crystal proteins. The CryIIIC protein may be utilized as the active ingredient in insecticidal formulations useful for the control of coleopteran insects such as those mentioned above. Such insecticidal formulations or compositions typically contain agriculturally acceptable carriers or adjuvants in addition to the active ingredient.

The CryIIIC protein may be employed in insecticidal formulations in isolated or purified form, e.g., as the crystal protein itself. Alternatively, the CryIIIC protein may be present in the recovered fermentation solids, obtained from culturing of a Bacillus strain, e.g., Bacillus thuringiensis, or other microorganism host carrying

- 18 -

the cryIIIC gene and capable of producing the CryIIIC protein. Preferred Bacillus hosts include B.t. strain EG4961 and genetically improved B.t. strains derived from B.t. strain EG4961. The
5 latter B.t. strains may be obtained via plasmid curing and/or conjugation techniques and contain the native cryIIIC gene-containing plasmid from B.t. strain EG4961. Genetically engineered or transformed B.t. strains or other host
10 microorganisms containing a recombinant plasmid that expresses the cloned cryIIIC gene, obtained by recombinant DNA procedures, may also be used.

Examples of such transformants include B.t. strains EG7231 and EG7220, both of which
15 contain the cloned cryIIIC gene on a recombinant plasmid.

The recovered fermentation solids contain primarily the crystal protein and (if a sporulating B.t. host is employed) spores; cell debris and
20 residual fermentation medium solids may also be present. The recovered fermentation solids containing the CryIIIC protein may be dried, if desired, prior to incorporation in the insecticidal formulation.

25 The formulations or compositions of this invention containing the insecticidal CryIIIC protein as the active component are applied at an insecticidally effective amount which will vary depending on such factors as, for example, the
30 specific coleopteran insects to be controlled, the specific plant or crop to be treated and the method of applying the insecticidally active compositions.

- 19 -

An insecticidally effective amount of the insecticide formulation is employed in the insect control method of this invention.

The insecticide compositions are made by
5 formulating the insecticidally active component with the desired agriculturally acceptable carrier. The formulated compositions may be in the form of a dust or granular material, or a suspension in oil (vegetable or mineral) or water or oil/water
10 emulsions, or as a wettable powder, or in combination with any other carrier material suitable for agricultural application. Suitable agricultural carriers can be solid or liquid and are well known in the art. The term
15 "agriculturally acceptable carrier" covers all adjuvants, e.g., inert components, dispersants, surfactants, tackifiers, binders, etc. that are ordinarily used in insecticide formulation technology; these are well known to those skilled
20 in insecticide formulation.

The formulations containing the CryIIIC protein and one or more solid or liquid adjuvants are prepared in known manners, e.g., by
homogeneously mixing, blending and/or grinding the
25 insecticidally active CryIIIC protein component with suitable adjuvants using conventional formulation techniques.

The CryIIIC protein, and other coleopteran toxin proteins such as CryIIIB and
30 CryIIIA, may also be used in combination with a CryI protein, to provide unexpectedly enhanced insecticidal activity against a coleopteran insect target. The coleopteran-specific activity of

- 20 -

CryIIIC, CryIIIB and CryIIIA proteins is greatly enhanced by the addition or incorporation of a CryI protein into an insecticidal composition containing such CryIII protein. This method may be employed
5 to make synergistic CryIII-CryI protein insecticide compositions, via physical combination of the respective CryIII and CryI proteins or via combination of B.t. strains making the respective proteins. The preferred CryI protein for use in
10 the synergistic CryIII insecticide combinations is CryIA, and particularly, CryIA(c), although it is believed that other CryI proteins can also be used in the synergistic combinations. Surprisingly, there appears to be no enhancement of the CryI
15 protein's insecticidal efficacy against lepidopteran insects; i.e., there seems to be no "reverse synergy" with CryI proteins imparted by the presence of CryIII crystal proteins.

If desired, combinations of CryIIIC (or
20 CryIIIB) and CryI proteins in this invention may be obtained in situ in combined form, from cultures of strains of B.t. or other microorganism hosts carrying such cryIII genes and cryI genes capable of producing the respective CryIII and CryI
25 proteins. Such strains or hosts may be obtained via plasmid curing and/or conjugation techniques involving B.t. or other strains or host microorganisms containing a recombinant plasmid that expresses the cloned cryIII and cryI genes.

30 An amount of CryI protein approximately equivalent to the quantity of CryIII protein present in the composition provides good enhancement of coleopteran-specific insecticidal

- 21 -

activity. Smaller amounts of CryI protein than this 1:1 CryI:CryIII ratio will likely still give satisfactory levels of enhancement to the CryIII protein.

- 5 The insecticidal compositions of this invention are applied to the environment of the target coleopteran insect, typically onto the foliage of the plant or crop to be protected by conventional methods, preferably by spraying.
- 10 Other application techniques, e.g., dusting, sprinkling, soaking, soil injection, seed coating, seedling coating or spraying, or the like, are also feasible and may be required for insects that cause root or stalk infestation. These application
- 15 procedures are well known in the art.

- The cryIIIC gene or its functional equivalent, hereinafter sometimes referred to as the "toxin gene," can be introduced into a wide variety of microorganism hosts. Expression of the
- 20 cryIIIC gene results in the production of insecticidal CryIIIC crystal protein toxin. Suitable hosts include B.t. and other species of Bacillus, such as B. subtilis or B. megaterium, for example. Plant-colonizing or root-colonizing
- 25 microorganisms may also be employed as the host for the cryIIIC gene. Various procedures well known to those skilled in the art are available for introducing the cryIIIC gene into the microorganism host under conditions which allow for stable
- 30 maintenance and expression of the gene in the resulting transformants.

- 22 -

The transformants, i.e., host microorganisms that harbor a cloned gene in a recombinant plasmid, can be isolated in accordance with conventional methods, usually employing a selection technique, which allows growth of only those host microorganisms that contain a recombinant plasmid. The transformants then can be tested for insecticidal activity. Again, these techniques are standard procedures.

Characteristics of particular interest in selecting a host cell for purposes of production include ease of introducing the gene into the host, availability of expression systems, efficiency of expression, stability of the CryIIIC insecticidal protein in the host, and the presence of auxiliary genetic capabilities. The cellular host containing the insecticidal cryIIIC gene may be grown in any convenient nutrient medium, where expression of the cryIIIC gene is obtained and CryIIIC protein produced, typically to sporulation. The sporulated cells containing the crystal protein may then be harvested in accordance with conventional methods, e.g., centrifugation or filtration.

The cryIIIC gene may also be incorporated into a plant which is capable of expressing the gene and producing CryIIIC protein, rendering the plant more resistant to insect attack. Genetic engineering of plants with the cryIIIC gene may be accomplished by introducing the desired DNA containing the gene into plant tissues or cells, using DNA molecules of a variety of forms and origins that are well know to those skilled in plant genetic engineering. An example of a

- 23 -

technique for introducing DNA into plant tissue is disclosed in European Patent Application Publication No. 0 289 479, published November 2, 1988, of Monsanto Company.

5 DNA containing the cryIIIC gene or a modified cryIIIC gene capable of producing the CryIIIC protein may be delivered into the plant cells or tissues directly by infectious plasmids, such as Ti, the plasmid from Agrobacterium
10 tumefaciens, viruses or microorganisms like A. tumefaciens, by the use of lysosomes or liposomes, by microinjection by mechanical methods and by other techniques familiar to those skilled in plant engineering.

15 Variations may be made in the cryIIIC gene nucleotide base sequences, since the various amino acids forming the protein encoded by the gene usually may be determined by more than one codon, as is well known to those skilled in the art.
20 Moreover, there may be some variations or truncation in the coding region of the cryIIIC nucleotide base sequence which allow expression of the gene and production of functionally equivalent forms of the CryIIIC insecticidal protein. These
25 variations which can be determined without undue experimentation by those of ordinary skill in the art with reference to the present specification are to be considered within the scope of the appended claims, since they are fully equivalent to the
30 specifically claimed subject matter.

The present invention will now be described in more detail with reference to the following specific, non-limiting examples. The

- 24 -

examples relate to work which was actually done based on techniques generally known in the art and using commercially available equipment.

The novel B.t. strain EG4961 was isolated
5 following the procedure described in Example 1.

Example 1

Isolation of B.t. Strain EG4961

Crop dust samples were obtained from various sources throughout the U.S. and abroad,
10 typically grain storage facilities. The crop dust samples were treated by suspending the crop dust in an aqueous buffer and heating the suspension at 60°C for 30 min. to enrich for heat resistant spore forming Bacillus-type bacteria such as B.t. The
15 treated dust suspensions were diluted in aqueous buffer, and the dilutions were spread on agar plates to allow each individual bacterium from the crop dust to grow into a colony on the surface of the agar plate. After growth, a portion of each
20 colony was transferred from the agar plate to a nitrocellulose filter. The filter was treated with NaOH to lyse the colonies and to fix the DNA from each colony onto the filter.

A modified treatment procedure was
25 developed for use with B.t. colonies utilized in the colony hybridization procedure, since standard techniques applicable to E. coli were found to be unworkable with B.t. In the treatment described above, special conditions were required to assure
30 that the B.t. colonies were in a vegetative state of growth, making them susceptible to lysis with NaOH. Accordingly, after a portion of each colony

- 25 -

was transferred to the nitrocellulose filter, the filter was placed colony side up on an agar medium containing 0.5% (w/v) glucose. The transferred colonies were then allowed to grow on the agar-glucose medium for 5 hours at 30°C. Use of 0.5% glucose in the agar medium and the 5-hour, 30°C growth cycle were critical for assuring that the B.t. colonies were in a vegetative state and thus susceptible to lysis.

10 Despite the opinion expressed by at least one researcher that attempts to use an existing coleopteran toxin gene as a probe to discover a novel gene that was toxic to the southern corn rootworm would be unsuccessful, a cloned
15 coleopteran toxin gene was used as a specific probe to find other novel and rare coleopteran-toxic strains of B.t. from crop dust samples.

A 2.9 kb HindIII DNA restriction fragment containing the cryIIIA gene, formerly known as the
20 cryC gene of B.t. strain EG2158, described in Donovan et al., Mol. Gen. Genet., 214, pp. 365-372 (1988), was used as a probe in colony hybridization procedures.

The 2.9 kb HindIII cryIIIA DNA fragment,
25 containing the entire cryIIIA gene, was radioactively labeled with alpha-P³² dATP and Klenow enzyme, by standard methods. The nitrocellulose filters containing the DNA from a lysed colony were incubated at 65°C for 16 hours in
30 a buffered solution that contained the radioactively labeled 2.9 kb HindIII cryIIIA DNA probe to hybridize the DNA from the colonies with the DNA from the radioactively labeled cryIIIA

- 26 -

probe. The 65°C hybridization temperature was used to assure that the cryIIIA DNA probe would hybridize only to DNA from colonies that contained a gene that was similar to the cryIIIA DNA probe.

5 The 2.9 kb cryIIIA probe hybridized to many B.t. colonies from various samples of crop dust. Examination of these colonies revealed, unexpectedly, that they did not contain any cryIII-type genes. These colonies did contain
10 cryI-type genes. The cryI-type genes encode lepidopteran-toxic, coleopteran-nontoxic crystal proteins with molecular masses of approximately 130 kDa. Computer-assisted comparisons of the sequence of the cryIIIA gene with the sequence of several
15 cryI-type genes revealed that the 3'-end of the cryIIIA gene was partially homologous with portions of the cryI-type genes. This finding supported the belief that the 3'-end of the cryIIIA gene was causing the 2.9 kb cryIIIA probe to hybridize to
20 B.t. colonies containing cryI-type genes.

To correct this problem, the 2.9 kb HindIII cryIIIA probe was digested with the enzyme XbaI and a 2.0 kb HindIII-XbaI fragment was purified that contained the cryIIIA gene minus its
25 3'-end. The 2.0 kb HindIII-XbaI fragment contains the 3'-truncated cryIIIA gene. When the 2.0 kb fragment was used in repeated colony hybridization experiments, it did not hybridize to cryI gene-containing B.t. colonies.

30 Approximately 48,000 Bacillus-type colonies from crop dust samples from various locations were probed with the radioactively labeled 2.0 kb HindIII-XbaI cryIIIA probe. Only

- 27 -

one novel B.t. strain from an Illinois crop dust sample was discovered that specifically hybridized to the cryIIIA probe. That novel strain was designated B.t. strain EG2838, which has been
5 deposited with the NRRL under Accession No. NRRL B-18603.

Subsequently, an additional 50,000 Bacillus-type colonies from crop dust samples were also screened with the radioactively labeled 2.0 kb
10 HindIII-XbaI cryIIIA probe, but without success in identifying any other strains containing novel cryIII-type genes.

B.t. strain EG2838 was found to be insecticidally active against coleopteran insects,
15 notably, the Colorado potato beetle. B.t. strain EG2838 did not have substantial insecticidal activity with respect to the southern corn rootworm. A gene, designated the cryIIIB gene, was isolated from B.t. strain EG2838, and its
20 nucleotide base sequence determined. The cryIIIB encoded a crystal protein, designated the CryIIIB protein, containing 651 amino acids having a deduced size of 74,237 Daltons. The size of the prior art CryIIIA protein had previously been
25 deduced to be 73,116 Daltons (644 amino acids). The cryIIIB gene is 75% homologous with the cryIIIA gene, and the CryIIIB protein is 68% homologous with the CryIIIA protein.

Approximately 40,000 Bacillus-type
30 colonies from thirty-nine crop dust samples from various locations from around the world were screened with a cryIIIB probe obtained from B.t. strain EG2838. The cryIIIB probe was radioactively

- 28 -

labeled using the procedure set forth above with respect to the radioactively labeled cryIIIA probe. The radioactively labeled cryIIIB probe consisted of a 2.4 kb SspI restriction fragment of DNA from 5 B.t. strain EG2838. The fragment contains the complete protein coding region for the coleopteran toxin cryIIIB gene of B.t. strain EG2838. Ultimately, a novel B.t. strain from a crop dust sample was discovered that specifically hybridized 10 to the cryIIIB probe. The strain was designated B.t. strain EG4961.

To characterize B.t. strain EG4961, several studies were conducted. One series of studies was performed to characterize its flagellar 15 serotype. Additional studies were conducted to determine the sizes of the native plasmids in B.t. strain EG4961 and to ascertain which plasmids contained genes that encode insecticidal crystal proteins. DNA blot analysis was performed to 20 determine whether any of the native plasmids of B.t. strain EG4961 hybridized with the cryIIIB probe. Also of interest was whether the cryIIIB-hybridizing DNA element of B.t. strain EG4961 was carried on a single naturally occurring plasmid, as 25 opposed to being carried on multiple plasmids or on the chromosomal DNA. In addition, B.t. strain EG4961 was evaluated further by characterizing the crystal proteins it produced and by measuring the insecticidal activity associated with B.t. strain 30 EG4961 and its crystal proteins. Examples 2 through 6 are directed to the procedures for

- 29 -

characterizing B.t. strain EG4961, and Examples 8 through 12 are directed to the insecticidal activity of B.t. strain EG4961.

Example 2

5 Characterization of the Flagellar Serotype of B.t. Strain EG4961

 A panel of B.t. type-strain flagellar antibody reagents was constructed for use in serotyping investigations, using B.t. type-strains
10 that are publicly available. B.t. type-strains HD1 (kurstaki, serotype 3ab), HD2 (thuringiensis, serotype 1), HD5 (kenyae, serotype 4ac), HD11 (aizawai, serotype 7), HD12 (morrisoni, serotype 8ab) and HD13 (tolworthi, serotype 9) were grown in
15 liquid cultures (no shaking) under conditions that produce motile, vegetative cells. Flagellar filaments were sheared from the cells by vortexing, cells were removed by centrifugation, and flagellar filaments were collected from the supernatants on
20 0.2 μ m pore size filters. Purified flagellar filament preparations were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The SDS-PAGE profiles for these B.t. type-strain flagellar filament preparations showed
25 a major protein band for each of these preparations in the range of 20 to 35 kDa.

 These purified flagellar filament preparations were used for antibody production in mice following standard procedures. The resulting
30 antisera were screened for reaction in a standard antibody-mediated cell agglutination assay. In this assay, serial dilutions of antisera were made in a round bottomed 96-well microplate. Formalin-

- 30 -

fixed cell suspensions of B.t. type-strains (or sample strains to be serotyped) were added to the wells and left undisturbed until cell mass was visible near well bottoms. Assays were scored visually for cell agglutination from the bottom of the plate using a magnifying mirror. Antisera giving the strongest specific reaction with cells of the B.t. type-strain from which they were derived were used as flagellar antibody reagents.

Cells from each of B.t. strains EG2158 and EG4961 were separately inputted as samples in a cell agglutination assay using a panel of flagellar antibody reagents from the six B.t. type-strains. Cells of each B.t. type-strain were included as controls. Results of this investigation showed that cells of HD1, HD2, HD5, HD11, HD12 and HD13, B.t. type-strains reacted strongly and specifically with their respective flagellar antibody reagents. B.t. strain EG2158 cells reacted strongly and specifically with the morrisoni (B.t. type-strain HD12) flagellar antibody reagent, but cells from B.t. strain EG4961 did not react with any of the antibody reagents. These results confirm that B.t. strain EG2158 is a subspecies morrisoni B.t. strain and indicate that B.t. strain EG4961 is not a subspecies morrisoni, kurstaki, thuringiensis, kenyae, aizawai or tolworthi.

Example 3

Size Fractionation and cryIIIB Probing of Native Plasmids of EG4961

B.t. strains may be characterized by fractionating their plasmids according to size by the well-known procedure called agarose gel

- 31 -

electrophoresis. The procedure involves lysing B.t. cells with lysozyme and SDS, electrophoresing plasmids from the lysate through an agarose gel and staining the gel with ethidium bromide to visualize the plasmids. Larger plasmids, which move more slowly through the gel, appear at the top of the gel and smaller plasmids appear toward the bottom of the gel.

The agarose gel in Figure 2 shows that B.t. strain EG4961 contains native plasmids of approximately 150, 95, 70, 50, 5 and 1.5 MDa, as indicated by the dark horizontal bands. Plasmid sizes were estimated by comparison to plasmids of known sizes (not shown). Figure 2 further shows that the coleopteran-toxic B.t. strain EG2838 contains native plasmids of about 100, 90 and 37 MDa. Figure 2 also shows that the coleopteran-toxic B.t. strain EG2158 contains native plasmids of about 150, 105, 88, 72, and 35 MDa. Some of the plasmids, such as the 150 and 1.5 MDa plasmids of B.t. strain EG4961 and the 150 MDa plasmid of B.t. strain EG2158, may not be visible in the photograph, although they are visible in the actual gel. Figure 2 demonstrates that the sizes of the native plasmids of B.t. strain EG4961 are different from the sizes of the native plasmids of B.t. strains EG2158 and EG2838.

The plasmids shown in Figure 2 were transferred by blotting from the agarose gel to a nitrocellulose filter using the blot techniques of Southern, J. Molec. Biol., 98, pp. 503-517 (1975), and the filter was hybridized as described above with the radioactively labeled 2.4 kb cryIIIB DNA

- 32 -

probe. After hybridization, the filter was exposed to X-ray film. A photograph of the X-ray film is shown in Figure 3 which shows by the darkened area that the cryIIIB probe hybridized to the 95 MDa
5 plasmid of B.t. strain EG4961. This result demonstrates that the 95 MDa plasmid of B.t. strain EG4961 contains a DNA sequence that is at least partly homologous to the cryIIIB gene. Figure 3 also shows that the cryIIIB probe hybridized, as
10 expected, to the 88 MDa plasmid of B.t. strain EG2158 and to the 100 MDa plasmid of B.t. strain EG2838. The 88 MDa plasmid of B.t. strain EG2158 has been previously shown to contain the coleopteran-toxin cryIIIA gene (see Donovan et al.,
15 Mol. Gen. Genet., 214, pp. 365-372 (1988)). It has been determined that the 100 MDa plasmid of B.t. strain EG2838 contains the coleopteran toxin cryIIIB gene.

The cryIIIB probe also hybridized to
20 small bands of DNA in each of B.t. strains EG4961, EG2838 and EG2158 that are indicated by the letter "f" in Figure 3. Previous experience has shown that large B.t. plasmids often break into fragments during electrophoresis. These fragments normally
25 migrate to the position of the bands indicated by the letter "f" in Figure 3. Therefore, the bands indicated by the letter "f" in Figure 3 are most likely derived by fragmentation of the 95 MDa, 88 MDa and 100 MDa plasmids of B.t. strains EG4961,
30 EG2158 and EG2838, respectively.

- 33 -

Example 4Blot Analysis of DNA from B.t. Strain EG4961

Both chromosomal and plasmid DNA from B.t. strain EG4961 was extracted and digested with HindIII plus EcoRI restriction enzymes. The digested DNA was size fractionated by electrophoresis through an agarose gel, and the fragments were visualized by staining with ethidium bromide. Figure 4 is a photograph of the stained agarose gel that contains size fractionated HindIII and EcoRI restriction fragments of B.t. strain EG4961. For comparison, the DNA from the coleopteran-toxic B.t. strains EG2158 and EG2838 was processed in an identical manner. The lane labeled "stnd" contains lambda DNA fragments of known sizes, which serve as size standards. Figure 4 shows that HindIII plus EcoRI digested B.t. DNA yields hundreds of DNA fragments of various sizes.

The DNA shown in Figure 4 was transferred from the agarose gel to a nitrocellulose filter, and the filter was hybridized at 65°C in a buffered aqueous solution containing the radioactively labeled 2.4 kb cryIIIB DNA probe. After hybridization, the filter was exposed to X-ray film. Figure 5 is a photograph of the X-ray film where the numbers to the right indicate the size, in kb, of the cryIIIB hybridizing fragments of B.t. strain EG4961 as determined by comparison with lambda DNA digested with HindIII as a size marker in the lane labeled "stnd". Figure 5 shows that HindIII plus EcoRI digested DNA of B.t. strain EG4961 yields cryIIIB-hybridizing fragments of approximately 3.8 kb and 2.4 kb. Figure 5 also

- 34 -

shows that HindIII plus EcoRI digested DNA of B.t. strain EG2838 yields cryIIIB-hybridizing fragments of approximately 2.9 kb and 3.8 kb. Figure 5 further shows that the approximate sizes of

5 cryIIIB-hybridizing restriction DNA fragments of B.t. strain EG2158 are 1.6 kb and 0.7 kb.

These results suggest that B.t. strain EG4961 contains a cryIII-type gene that is related to the cryIIIB gene probe. The cryIIIB-hybridizing

10 fragments of B.t. strain EG4961 are different from those of B.t. strains EG2838 and EG2158. These results and further studies described in the Examples below confirm that the cryIII-type gene of

15 cryIIIB gene of EG2838 and the cryIIIA gene of EG2158. The cryIII-type gene of B.t. strain EG4961 has been designated cryIIIC.

Example 5

Characterization of Crystal Proteins of B.t. Strain EG4961

20

B.t. strain EG4961 was grown in DSMG sporulation medium at 30°C until sporulation and cell lysis had occurred (3 to 4 days growth). The DSMG medium is 0.4% (w/v) Difco nutrient broth, 25

25 mM K_2HPO_4 , 25 mM KH_2PO_4 , 0.5 mM $Ca(NO_3)_2$, 0.5 mM $MgSO_4$, 10 μM $FeSO_4$, 10 μM $MnCl_2$ and 0.5% (w/v) glucose. The sporulated culture of B.t. strain EG4961 was observed microscopically to contain free floating, irregularly shaped crystals in addition

30 to B.t. spores. Experience has shown that B.t. crystals are usually composed of proteins that may be toxic to specific insects. The appearance of the crystals of B.t. strain EG4961 differed from

- 35 -

the flat, rectangular (or rhomboidal) crystals of B.t. strain EG2158, but partially resembled some of the irregularly shaped crystals of B.t. strain EG2838.

- 5 Spores, crystals and residual lysed cell debris from the sporulated culture of B.t. strain EG4961 were harvested by centrifugation. The crystals were specifically solubilized from the centrifuged fermentation culture solids (containing
- 10 crystals, spores and some cell debris) by heating the solids mixture in a solubilization buffer (0.13 M Tris pH 8.5, 2% (w/v) SDS, 5% (v/v) 2-mercaptoethanol, 10% (v/v) glycerol) at 100°C for 5 min. The solubilized crystal proteins were size
- 15 fractionated by SDS-PAGE. After size fractionation, the proteins were visualized by staining with Coomassie dye. Cultures of B.t. strains EG2158 and EG2838 are processed in an identical manner for purposes of comparison.
- 20 Figure 6 shows the results of these analyses where the numbers to the right indicate the size, in kDa, of the crystal proteins synthesized by B.t. strain EG4961. A major protein of approximately 70 kDa and a minor protein of
- 25 approximately 30 kDa were solubilized from centrifuged fermentation solids containing B.t. strain EG4961 spores and crystals. The approximately 70 kDa protein of B.t. strain EG4961 appears similar in size to the approximately 70 kDa
- 30 coleopteran-toxic crystal protein of B.t. strain EG2158 and to the approximately 70 kDa coleopteran-toxic crystal protein of B.t. strain EG2838. The minor crystal protein of approximately

- 36 -

30 kDa of B.t. strain EG4961 is roughly similar in size to crystal proteins of approximately 31 kDa and 29 kDa produced by B.t. strain EG2158 and to crystal proteins of approximately 28 kDa and 32 kDa produced by B.t. strain EG2838. It is not known whether these small proteins are related to one another.

Following the procedure of Example 4, further DNA blot analysis revealed that the 2.4 kb cryIIIB DNA probe specifically hybridized to a single 8.3 kb Asp718-PstI restriction fragment of B.t. strain EG4961 DNA. This result suggested that the 8.3 kb fragment contained the complete cryIIIC gene.

The 8.3 kb Asp718-PstI fragment of B.t. strain EG4961 was isolated and studies were conducted on the 8.3 kb Asp718-PstI restriction fragment to confirm that the fragment contained a cryIII-type gene and to identify and determine the nucleotide base sequence of the cryIIIC gene. The procedures are set forth in Example 6.

Example 6

Cloning and Sequencing of the cryIIIC Gene of B.t. Strain EG4961

To clone the 8.3 kb fragment described in the previous Example, a plasmid library of B.t. strain EG4961 was constructed by ligating size-selected DNA Asp718-PstI restriction fragments from B.t. strain EG4961 into the well-known E. coli vector pUC18. This procedure involved first obtaining total DNA from B.t. strain EG4961 by cell lysis followed by spooling, then double digesting the total DNA with both Asp718 and PstI restriction

- 37 -

enzymes, electrophoresing the digested DNA through an agarose gel, excising a gel slice containing 7 kb-9 kb size selected fragments of DNA, and electroeluting the size selected Asp718-PstI restriction fragments from the agarose gel slice. The selected fragments were mixed with the E. coli plasmid vector pUC18, which had also been digested with Asp718 and PstI. The pUC18 vector carries the gene for ampicillin resistance (Amp^r) and the vector replicates in E. coli. T4 DNA ligase and ATP were added to the mixture of size-selected restriction fragments of DNA from B.t. strain EG4961 and of digested pUC18 vector to allow the pUC18 vector to ligate with the B.t. strain EG4961 restriction fragments.

The plasmid library was then transformed into E. coli cells, a host organism lacking the gene of interest, as follows. After ligation, the DNA mixture was incubated with an ampicillin sensitive E. coli host strain, E. coli strain HB101, that had been treated with $CaCl_2$ to allow the cells to take up the DNA. E. coli, specifically strain HB101, was used as the host strain because these cells are easily transformed with recombinant plasmids and because E. coli strain HB101 does not naturally contain genes for B.t. crystal proteins. Since pUC18 confers resistance to ampicillin, all host cells acquiring a recombinant plasmid would become ampicillin-resistant. After exposure to the recombinant plasmids, the E. coli host cells were spread on agar medium that contained ampicillin. Several thousand E. coli colonies grew on the ampicillin-

- 38 -

containing agar from those cells which harbored a recombinant plasmid. These E. coli colonies were then blotted onto nitrocellulose filters for subsequent probing.

5 The radioactively labeled 2.4 kb cryIIIB gene probe was then used as a DNA probe under conditions that permitted the probe to bind specifically to those transformed host colonies that contained the 8.3 kb Asp718-PstI fragment of
10 DNA from B.t. strain EG4961. Twelve E. coli colonies specifically hybridized to the 2.4 kb cryIIIB probe. One cryIIIB-hybridizing colony, designated E. coli strain EG7218, was studied further. E. coli strain EG7218 contained a
15 recombinant plasmid, designated pEG258, which consisted of pUC18 plus the 8.3 kb Asp718-PstI restriction fragment of DNA. The cryIIIB probe specifically hybridized to the 8.3 kb fragment of pEG258. A restriction map of pEG258 is shown in
20 Figure 7.

 The 8.3 kb fragment of pEG258 contained HindIII fragments of 2.4 kb and 3.8 kb, and a BamHI-XbaI fragment of 4.0 kb that specifically hybridized with the cryIIIB probe. The 2.4 kb
25 HindIII fragment was subcloned into the DNA sequencing vector M13mp18. The 4.0 kb BamHI-XbaI fragment was subcloned into the DNA sequencing vectors M13mp18 and M13mp19.

 The nucleotide base sequence of a
30 substantial part of each subcloned DNA fragment was determined using the standard Sanger dideoxy method. For each subcloned fragment, both DNA strands were sequenced by using sequence-specific

- 39 -

17-mer oligonucleotide primers to initiate the DNA sequencing reactions. Sequencing revealed that the 8.3 kb fragment contained an open reading frame and, in particular, a new cryIII-type gene. This
5 new gene, designated cryIIIC, is significantly different from the cryIIIA gene. As indicated below, cryIIIC gene is also clearly distinct from the cryIIIB gene.

The DNA sequence of the cryIIIC gene and
10 the deduced amino acid sequence of the CryIIIC protein encoded by the cryIIIC gene are shown in Figure 1. The protein coding portion of the cryIIIC gene is defined by the nucleotides starting at position 14 and ending at position 1972. The
15 probable ribosome binding site is indicated as "RBS" in Figure 1-1. The size of the CryIIIC protein encoded by the cryIIIC gene, as deduced from the open reading frame of the cryIIIC gene, is 74,393 Daltons (651 amino acids). It should be
20 noted that the apparent size of the CryIIIC protein, as determined from SDS-PAGE, is approximately 70 kDa. Therefore, the CryIIIC protein will be referred to in this specification as being approximately 70 kDa in size.

25 The size of the prior art CryIIIA protein has previously been deduced to be 73,116 Daltons (644 amino acids). The size of the CryIIIB protein has previously been determined to be 74,237 Daltons (651 amino acids).

30 DNA sequencing revealed the presence of BamHI and HindIII restriction sites within the cryIIIC gene (See Figure 1-2). Knowledge of the locations of these restriction sites permitted the

- 40 -

precise determination of the location and orientation of the cryIIIC gene within the 8.3 kb fragment as indicated by the arrow in Figure 7.

The computer program of Queen and Korn
5 (C. Queen and L.J. Korn, "Analysis of Biological Sequences on Small Computers," DNA, 3, pp. 421-436 (1984)) was used to compare the sequences of the cryIIIC gene to the cryIIIB and cryIIIA genes and to compare the deduced amino acid sequences of
10 their respective CryIIIC, CryIIIB and CryIIIA proteins.

The nucleotide base sequence of the cryIIIC gene was 96% positionally identical with the nucleotide base sequence of the cryIIIB gene
15 and only 75% positionally identical with the nucleotide base sequence of the cryIIIA gene. Thus, although the cryIIIC gene is related to the cryIIIB and cryIIIA genes, it is clear that the cryIIIC gene is distinct from the cryIIIB gene and
20 substantially different from the cryIIIA gene.

The deduced amino acid sequence of the CryIIIC protein was found to be 94% positionally identical to the deduced amino acid sequence of the CryIIIB protein, but only 69% positionally
25 identical to the deduced amino acid sequence of the CryIIIA protein. These differences, together with the differences in insecticidal activity as set forth below, clearly show that the CryIIIC protein encoded by the cryIIIC gene is a different protein
30 from the CryIIIB protein or the CryIIIA protein.

Moreover, while not wishing to be bound by any theory, based on a comparison of the amino acid sequences of the CryIIIC protein and the

- 41 -

CryIIIB protein, it is believed that the following amino acid residues may be of significance for the enhanced corn rootworm toxicity of the CryIIIC protein, where the numbers following the accepted abbreviations for the amino acids indicate the position of the amino acid in the sequence illustrated in Figure 1: His9, His231, Gln339, Phe352, Asn446, His449, Val450, Ser451, Lys600 and Lys624. These amino acid residues were selected as being of probable significance for the corn rootworm toxicity of the CryIIIC protein because, after studying the amino acid sequences of several other CryIII proteins, the amino acids at the indicated positions fairly consistently showed different amino acids than those indicated for the CryIIIC protein.

Example 7

Expression of the Cloned cryIIIC Gene

Studies were conducted to determine the production of the CryIIIC protein by the cryIIIC gene.

Table 1 summarizes the relevant characteristics of the B.t. and E. coli strains and plasmids used during these procedures. A plus (+) indicates the presence of the designated element, activity or function and a minus (-) indicates the absence of the same. The designations ^S and ^R indicate sensitivity and resistance, respectively, to the antibiotic with which each is used. The abbreviations used in the table have the following meanings: Amp (ampicillin); Cm (chloramphenicol); Cry (crystalliferous); Tc (tetracycline).

- 42 -

Table 1Strains and Plasmids

<u>Strain or plasmid</u>	<u>Relevant characteristics</u>
<u>B. thuringiensis</u>	
5 HD73-26	Cry ⁻ , Cm ^S
EG7211	HD73-26 harboring pEG220(Cry ⁻)
EG7220	HD73-26 harboring pEG260(<u>cryIIIC⁺</u> <u>cryX⁺</u>)
EG7231	HD73-26 harboring pEG269(<u>cryIIIC⁺</u> <u>cryX⁻</u>)
EG4961	<u>cryIIIC⁺</u> <u>cryX⁺</u>
10 <u>E. coli</u>	
DH5α	Cry ⁻ , Amp ^S
GM2163	Cry ⁻ , Amp ^S
EG7218	DH5α harboring pEG258(<u>cryIIIC⁺</u> <u>cryX⁺</u>)
EG7221	DH5α harboring pUC18(Cry ⁻)
15 EG7232	DH5α harboring pEG268(<u>cryIIIC⁺</u> <u>cryX⁻</u>)
EG7233	DH5α harboring pEG269(<u>cryIIIC⁺</u> <u>cryX⁻</u>)
<u>Plasmids</u>	
pEG220	Amp ^r , Tc ^r , Cm ^r , Cry ⁻ , <u>Bacillus-E. coli</u>
20	shuttle vector consisting of pBR322 ligated into the <u>SphI</u> site of pNN101
pUC18	Amp ^r , Cry ⁻ , <u>E. coli</u> vector
pNN101	Cm ^r , Tc ^r , Cry ⁻ , <u>Bacillus</u> vector
pEG258	Amp ^r , <u>cryIIIC⁺</u> <u>cryX⁺</u> <u>E. coli</u> recombinant
25	plasmid consisting of the 8.3 kb <u>Asp718-</u> <u>PstI</u> <u>cryIIIC⁺</u> <u>cryX⁺</u> fragment of <u>B.t.</u> strain EG4961 ligated into the <u>Asp718-PstI</u> sites of pUC18

- 43 -

Table 1 (continued)Strains and Plasmids

<u>Strain or plasmid</u>	<u>Relevant characteristics</u>
<u>Plasmids (continued)</u>	
5 pEG260	Tc ^r , Cm ^r , <u>cryIIIC⁺ cryX⁺ Bacillus</u> recombinant plasmid consisting of the 8.3 kb <u>Asp718-PstI cryIIIC⁺ cryX⁺</u> fragment of <u>B.t.</u> strain EG4961 blunt ligated into the <u>EcoRV</u> site of pNN101
10 pEG268	Amp ^r <u>cryIIIC⁺ cryX⁻ E. coli</u> recombinant plasmid consisting of a 5 kb <u>Sau3A</u> fragment of <u>B.t.</u> strain EG4961 ligated into the <u>BamHI</u> site of pBR322
15 pEG269	Amp ^r (<u>E. coli</u>), Tc ^r and Cm ^r (<u>B.t.</u>), <u>cryIIIC⁺ cryX⁻</u> , recombinant shuttle plasmid consisting of pNN101 ligated into the <u>SphI</u> site of pEG268

E. coli cells harboring the cloned 8.3 kb fragment described in Example 6 were analyzed to
 20 determine if they produced the 70 kDa CryIIIC crystal protein.

Experience has shown that cloned B.t. crystal genes are poorly expressed in E. coli and highly expressed in B.t. Recombinant plasmid
 25 pEG258, constructed as set forth in Example 6, will replicate in E. coli, but not in B.t. To achieve a high level of expression of the cloned cryIIIC gene, the 8.3 kb cryIIIC fragment was transferred from pEG258 to a plasmid vector pNN101
 30 (Tc^r Cm^r Cry⁻) that is capable of replicating in B.t.

- 44 -

The plasmid construct pEG258 was isolated from E. coli strain EG7218 by lysozyme/SDS treatment, followed by ethanol precipitation of the plasmid DNA, all using standard procedures. The
5 pEG258 plasmid DNA was then used to transform cells of E. coli strain GM2163 made competent by the calcium chloride procedure described earlier in Example 6. E. coli strain GM2163 is a crystal negative (Cry^-) and ampicillin sensitive (Amp^S)
10 strain, constructed by the procedures of M.G. Marinus et al. in Mol. Gen. Genet., 192, pp. 288-289 (1983).

The plasmid construct pEG258 was again isolated, this time from the transformed E. coli
15 strain GM 2163, using the procedures just described. The isolated pEG258 plasmid DNA was digested with Asp718 and PstI. The digested plasmid was electrophoresed through an agarose gel and the 8.3 kb Asp718-PstI cryIIIC fragment was
20 electroeluted from the agarose gel. The 8.3 kb fragment was made blunt-ended by using T4 polymerase and deoxynucleotide triphosphates to fill in the Asp718 and PstI ends.

The blunt-ended 8.3 kb fragment was mixed
25 with the Bacillus vector pNN101 that had been digested with EcoRV. T4 DNA ligase and ATP were added to the mixture to allow the blunt-ended 8.3 kb fragment to ligate into the EcoRV site of the pNN101 vector. After ligation, the DNA mixture
30 was added to a suspension of B.t. strain HD73-26 cells. Cells of B.t. strain HD73-26 are crystal-negative (Cry^-) and chloramphenicol sensitive (Cm^S). Using electroporation techniques, the cells

- 45 -

of B.t. strain HD73-26 in the mixture were induced to take up the recombinant plasmid construct, consisting of pNN101 and the ligated 8.3 kb cryIIIC fragment, also present in the mixture. Thus, the
5 recombinant plasmid was transformed by electroporation into B.t. strain HD73-26.

After electroporation, the transformed B.t. cells were spread onto an agar medium containing 5 µg chloramphenicol and were incubated
10 about 16-18 hours at 30°C. Cells that had taken up the plasmid pNN101 would grow into colonies on the chloramphenicol agar medium whereas cells that had not absorbed the plasmid would not grow. Cm^{r} colonies were transferred onto nitrocellulose and
15 then probed with the radioactively labeled cryIIIB gene and one colony, designated B.t. strain EG7220, that specifically hybridized to the cryIIIB probe was studied further.

EG7220 contained a plasmid, designated
20 pEG260, that consisted of the 8.3 kb cryIIIC fragment inserted into the EcoRV site of the pNN101 vector. A restriction map of plasmid pEG260 is shown in Figure 8.

Cells of B.t. strain EG7220 were grown in
25 a sporulation medium containing chloramphenicol (5 µg/ml) at 23-25°C until sporulation and cell lysis had occurred (3-4 days). Microscopic examination revealed that the culture of B.t. strain EG7220 contained spores and free floating irregularly
30 shaped crystals.

Spores, crystals and cell debris from the sporulated fermentation culture of B.t. strain EG7220 were harvested by centrifugation. The

- 46 -

crystals were solubilized by heating the centrifuged fermentation solids mixture in solubilization buffer (0.13 M Tris pH 8.5, 2% (w/v) SDS, 5% (v/v) 2-mercaptoethanol, 10% (v/v) glycerol) at 100°C for 5 min. After heating, the mixture was applied to an SDS-polyacryamide gel and proteins in the mixture were size fractionated by electrophoresis. After size fractionization, the proteins were visualized by staining with Coomassie dye. A photograph of the Coomassie stained gel is shown in Figure 10.

Figure 10 shows that B.t. strain EG7220 produced a major protein of approximately 70 kDa and a minor protein of approximately 30 kDa. These proteins appeared to be identical in size with the major approximately 70 kDa protein and the minor approximately 30 kDa protein produced by B.t. strain EG4961 (Figure 10). This result demonstrates that the 8.3 kb fragment of pEG260 contains two crystal protein genes: one for the approximately 70 kDa protein and one for the approximately 30 kDa protein.

The gene encoding the approximately 70 kDa protein is the cryIIIC gene, and the encoded protein is the CryIIIC protein. The gene encoding the approximately 30 kDa crystal protein has been designated cryX, and the encoded protein has been designated CryX.

As expected and as illustrated in Figure 10, an isogenic control strain of B.t., designated EG7211, consisting of B.t. strain HD73-26 and harboring only the plasmid vector pEG220, did not produce the approximately 70 kDa protein or the

- 47 -

approximately 30 kDa protein. Plasmid pEG220 is an ampicillin resistant, tetracycline resistant, chloramphenicol resistant and crystal-negative E. coli-Bacillus shuttle vector consisting of pBR322
5 ligated into the SphI site of pNN101.

E. coli cells harboring the cloned 8.3 kb fragment containing the cryIIIC gene and the cryX gene were analyzed to determine whether they produced the approximately 70 kDa and approximately
10 30 kDa crystal proteins. E. coli cells harboring pEG258, designated strain EG7218, were grown to late stationary phase and cells were harvested by centrifugation. E. coli strain EG7218 cells were lysed and total cellular proteins were solubilized
15 by heating the cells in the protein buffer. The complement of proteins solubilized from E. coli EG7218 cells appeared identical to the complement of proteins solubilized from a negative control strain of E. coli, designated EG7221, that harbored
20 only the plasmid vector pUC18 as illustrated in Figure 10. This result demonstrates that E. coli cells harboring the cloned 8.3 kb cryIIIC fragment produce very little, if any, of either the approximately 70 kDa or the approximately 30 kDa
25 crystal proteins.

The following procedures were used to isolate the cryIIIC gene, responsible for making the approximately 70 kDa CryIIIC protein.

A Sau3A fragment of DNA from B.t. strain
30 EG4961 that contained the cryIIIC gene, but not the cryX gene, was cloned by using the cryIIIB gene as a probe. This was accomplished by partially digesting DNA from B.t. strain EG4961 with Sau3A,

- 48 -

electrophoresing the digested DNA through an agarose gel and excising a gel slice containing Sau3A fragments of 4 kb to 9 kb. The Sau3A fragments were electroeluted from the gel slice and
5 mixed with plasmid pBR322 vector that had been digested with BamHI. The Sau3A fragments were ligated with the pBR322 vector. The ligation mix was incubated with CaCl_2 -treated cells of E. coli strain DH5 α to allow the cells to take up plasmid
10 DNA.

After incubation, the cells were plated on agar plates containing ampicillin and LB medium (1% (w/v) Difco tryptone, 0.5% (w/v) Difco yeast extract, 0.5% (w/v) NaCl, pH 7.0), to select for
15 those cells that had absorbed plasmid DNA. Several hundred Amp^r transformant colonies were blotted onto nitrocellulose filters and the filters were probed with the radioactively labeled cryIIIB probe as described above in Example 1. The probe
20 hybridized to several colonies and the characterization of one of these colonies, designated EG7232, is further described here. E. coli strain EG7232 contained a plasmid, designated pEG268, that consisted of pBR322 plus an inserted
25 Sau3A-BamHI DNA fragment of approximately 5 kb. The inserted DNA fragment specifically hybridized to the radioactively labeled cryIIIB probe.

Plasmid pEG268 ($\text{Amp}^r \text{ Tc}^s$) will replicate in E. coli but not in B.t. To obtain a derivative
30 of pEG268 that could replicate in B.t., pEG268 was digested with SphI, mixed with the Bacillus plasmid pNN101 ($\text{CM}^r \text{ Tc}^r$) that had also been digested with SphI and the mixture was ligated. The ligation

- 49 -

mixture was incubated with a suspension of CaCl_2 -treated E. coli cells to allow the cells to take up DNA from the pEG268 plasmid ligated with pNN101. After incubation, the cells were plated on agar
5 plates containing LB medium and tetracycline, and several hundred tetracycline resistant colonies grew. Only those cells that had absorbed a plasmid consisting of pEG268 and pNN101 would be able to grow and form colonies in the presence of
10 tetracycline. The characterization of one of these Tc^r colonies, designated EG7233, was selected for further study. As expected, E. coli strain EG7233 was found to contain a plasmid, designated pEG269, that consisted of pNN101 inserted into the SphI
15 site of pEG268. A restriction map of pEG269 is shown in Figure 9.

The plasmid construct pEG269 was isolated from E. coli strain EG7233 by lysozyme/SDS treatment, followed by ethanol precipitation of the
20 plasmid DNA, all using standard procedures. The pEG269 plasmid DNA was then used to transform cells of E. coli strain GM2163 made competent by the calcium chloride procedure, all as described earlier.

25 The plasmid construct pEG269 was again isolated, this time from the transformed E. coli strain GM2163. The isolated pEG269 plasmid DNA was added to a suspension of cells of the crystal-negative, chloramphenicol-sensitive B.t. strain
30 HD73-26 and an electric current was passed through the mixture, such that pEG269 was transformed by electroporation into B.t. strain HD73-26. The cells were plated onto an agar plate containing LB

- 50 -

medium and chloramphenicol and, after incubation, several hundred Cm^{r} colonies grew. The characterization of one of these Cm^{r} colonies, designated EG7231, was selected for investigation.

- 5 As expected, B.t. strain EG7231 was found to contain pEG269.

Cells of B.t. strain EG7231 were grown in DSMG medium containing chloramphenicol at 20-23°C for 4 days. Microscopic examination showed that
10 the culture contained, in addition to spores, particles that resembled B.t. crystals. The culture solids including spores, crystals and cell debris were harvested by centrifugation and suspended in an aqueous solution at a concentration
15 of 100 mg of culture solids/ml. A portion of this suspension was mixed with solubilization buffer (0.13 M Tris pH 8.5, 2% w/v SDS, 5% v/v 2-mercapto-ethanol, 10% v/v glycerol), heated at 100°C for 5 minutes and the mixture was electrophoresed
20 through an SDS-polyacrylamide gel to size fractionate proteins. After size fractionation, the proteins were visualized by staining the gel with Coomassie dye. A photograph of the stained gel is included in Figure 10.

- 25 B.t. strain EG7231 produced a major protein of approximately 70 kDa that appeared to be identical in size to the approximately 70 kDa CryIIIC protein produced by B.t. strain EG4961, as indicated in Figure 10. B.t. strain EG7231 did not
30 produce any detectable amount of the approximately 30 kDa crystal protein (Figure 10). This result demonstrates that the cryX gene for the approximately 30 kDa crystal protein is located

- 51 -

within the region indicated by the dotted line in Figures 7 and 8. Furthermore, this shows that B.t. strain EG7231 contains the cryIIIC gene in isolated form.

5 The following Examples 8-12 describe the manner in which the insecticidal activity of B.t. strain EG4961 and of the CryIIIC protein was determined.

10 **Insecticidal Activity of B.t. Strain EG4961 and the CryIIIC Protein Compared to B.t. Strain EG2158, B.t. tenebrionis and the CryIIIA Protein**

Example 8

General Preparation and Testing Procedures for Insecticidal Bioassays

15 Fermentation concentrates. B.t. strains EG4961 and EG2158 and B.t. tenebrionis ("B.t.t.") were grown in a liquid sporulation medium at 30°C until sporulation and lysis had occurred. The medium contained a protein source, a carbohydrate
20 source, and mineral salts and is typical of those in the art. NaOH was added to adjust the medium to pH 7.5 prior to autoclaving. The fermentation broth was concentrated by centrifugation and refrigerated until use.

25 As used herein, "CryIII" crystal protein designates the crystal protein of approximately 70 kDa obtained from the cultures of each of B.t. strains EG4961 and EG2158 and B.t.t. being tested. The CryIII crystal proteins were purified from the

- 52 -

fermentation culture solids using sucrose density gradients. When using sucrose density gradients to separate the components of the fermentation culture of sporulated B.t., B.t. spores form a pellet at
5 the bottom of the gradient and B.t. crystals form a band at approximately the middle of the gradient. Thus, sucrose density gradients permit the separation of B.t. crystal proteins, in relatively pure form, from B.t. spores and other fermentation
10 culture solids. The separated CryIII crystal proteins were stored at 4°C until use.

Quantification of the amount of CryIII crystal protein in all samples bioassayed was determined using standard SDS-PAGE techniques.

15 The following insects were tested:

southern corn rootworm (SCRW)	<u>Diabrotica undecimpunctata howardi</u>
western corn rootworm (WCRW)	<u>Diabrotica virgifera virgifera</u>
Colorado potato beetle (CPB)	<u>Leptinotarsa decemlineata</u>
elm leaf beetle	<u>Pyrrhalta luteola</u>
20 imported willow leaf beetle	<u>Plagioderma versicolora</u>

Two types of bioassays were performed, one using an artificial diet and the other using a leaf dip.

Artificial diet bioassays. SCRW larvae
25 were bioassayed via surface contamination of an artificial diet similar to Marrone et al., J. Econ. Entomol., 78, pp. 290-293 (1985), but without formalin. Each bioassay consisted of eight serial aqueous dilutions with aliquots applied to the
30 surface of the diet. After the diluent (an aqueous 0.005% Triton® X-100 solution) had dried, first

- 53 -

instar larvae were placed on the diet and incubated at 28°C. Thirty-two larvae were tested per dose. Mortality was scored after 7 days. Data from replicated bioassays were pooled for probit analysis (R.J. Daum, Bull. Entomol. Soc. Am., 16, pp. 10-15 (1970)) with mortality corrected for control death, the control being the diluent only (W.S. Abbott, J. Econ. Entomol., 18, pp. 265-267 (1925)). Results are reported by amount of CryIII crystal protein per mm² of diet surface resulting in LC₅₀, the concentration killing 50% of the test insects. 95% confidence intervals are reported within parentheses.

First instar WCRW larvae were tested on the same artificial diet at one dose. Mortality was read at 48 hours.

First instar CPB larvae were tested using similar techniques, except for the substitution of BioServe's #9380 insect diet with potato flakes added for the artificial diet. Mortality was scored at three days instead of seven days.

Leaf dip bioassays. For insect species or stages where suitable artificial diets were not available, bioassays were conducted by dipping suitable natural food materials (leaves) into known treatment concentrations suspended in an aqueous 0.2% Triton® X-100 solution. After excess material had dripped off, the leaves were allowed to dry. Leaves dipped in 0.2% Triton® X-100 served as untreated controls. Five or ten insects were confined in a petri dish with a treated leaf and allowed to feed for 48 hours. SCRW adults, CPB adults, elm leaf beetle larvae and adults, and

- 54 -

imported willow leaf beetle larvae and adults were tested in this manner using appropriate food sources.

Any deviations from the above
5 methodologies are noted with the appropriate data.

Example 9

**Insecticidal activity of CryIII proteins
against CPB larvae, elm leaf beetles
and imported willow leaf beetle larvae**

10 B.t. strain EG4961 is similar in activity to the previously discovered B.t. strain EG2158 against CPB larvae when tested on artificial diet, as shown by the data in Table 2.

Table 2

15 **Insecticidal activity of B.t. strains EG4961 and EG2158
against first instar Colorado potato
beetle larvae in artificial diet bioassays**

			LC ₅₀ (95% C.I.)* in ng CryIII/mm ²	
<u>Sample Type</u>		<u>Assays</u>	<u>EG4961</u>	<u>EG2158</u>
20	Ferm. conc.	2	0.47 (0.39-0.57)	0.42 (0.35-0.50)
<u>Control mortality</u>			<u>3.1%</u>	

95% confidence interval set forth in parentheses

25 Leaf dip bioassays have also demonstrated that B.t. strain EG4961 is similar in activity to B.t. strain EG2158 and B.t.t. against elm leaf beetle larvae and adults and imported willow leaf beetle larvae.

- 55 -

Example 10

Insecticidal activity of B.t. strains
and CryIII Proteins against SCRW
larvae in artificial diet bioassays

5 B.t. strain EG4961 possesses unique
activity against SCRW larvae compared to B.t.
strain EG2158 and B.t.t. in artificial diet
bioassays, as shown by the bioassay data in
Table 3. The comparisons in Table 3 labeled "Ferm.
10 conc. #1" and "Ferm. conc. #2" were based on
different fermentation concentrates of B.t. strain
EG4961. Neither B.t. strain EG2158 nor B.t.t.
caused over 15% mortality at the highest dose
tested. In contrast, LC_{50} values (i.e., 50%
15 mortality at the specified dose) were obtained for
B.t. strain EG4961 (Table 3).

When the purified CryIIIC crystal protein
of B.t. strain EG4961 was bioassayed, the activity
observed was only slightly less than that obtained
20 with B.t. strain EG4961 fermentation concentrates
(containing spores and crystals). This result
identified the CryIIIC crystal protein as the toxic
agent in B.t. strain EG4961. Surviving larvae in
the B.t. strain EG4961 bioassays (both fermentation
25 concentrates and purified crystal protein) were
extremely stunted in growth compared to the
untreated control larvae.

What little activity the fermentation
concentrate of B.t. strain EG2158 had against SCRW
30 larvae was lost when its purified CryIIIA crystal
protein was assayed alone. Even with the
concentration of purified CryIIIA protein increased
five-fold over the corresponding amount of CryIIIC
crystal protein, SCRW activity was non-existent for

- 56 -

the CryIIIA protein. The minimal activity of B.t. strain EG2158 as a fermentation concentrate may have been dependent on the presence of spores along with the CryIIIA crystal protein.

5

Table 3

Insecticidal activity of B.t. strain EG4961
against SCRW larvae in artificial diet bioassays

		<u>LC₅₀ (95% C.I.) in ng CryIII/mm²</u>			
	<u>Sample type</u>	<u># assays</u>	<u>EG4961</u>	<u>EG2158</u>	<u>B.t.t.</u>
10	Ferm. conc. #1	4	170 (139-213)	14% dead @ 1000	not tested
	Control mortality #1		9.4%		
	Ferm. conc. #2	4	206 (161-273)	not tested	15% dead @ 1000
15	Control mortality #2		8.6%		
	Purified protein crystals	4	645 (521-819)	3% dead @ 5000	not tested
	Control mortality		8.3%		

20 An artificial diet bioassay testing B.t.
strain EG4961 fermentation concentrate at one dose
against WCRW larvae yielded mortality similar to
that observed with SCRW larvae. As with SCRW
larvae, B.t.t. yielded little mortality greater
25 than the control.

- 57 -

Example 11

Insecticidal activity of B.t. strains EG4961, EG2158 and B.t.t. against adult SCRW and adult CPB in leaf dip bioassays

- 5 In addition to its unique activity against SCRW larvae, B.t. strain EG4961 also exhibits unique insecticidal activity to adult stages of both SCRW and CPB (Table 4) which are relatively unaffected by B.t. strain EG2158 or
- 10 B.t.t. Insect bioassay data from these studies are shown in Table 4.

Table 4

Insecticidal activity of B.t. strains EG4961, EG2158 and B.t.t. against adult SCRW and adult CPB in leaf dip bioassays

15			% dead at 48 hrs.	
	Strain	µg CryIII/ml	SCRW	CPB
20	EG4961	2800	50	100
		1400	37.5	98
		700	25	95
		350	10	70
	EG2158	4350	-	-
		2175	-	0
		1088	-	10
		544	-	-
25	B.t.t.	2250	0	0
		1125	10	5
		563	0	0
	Control mortality		0	0

(-) dashes indicate not tested.

- 58 -

Example 12Insecticidal activity of the cloned cryIIIC gene

B.t. strain EG4961 and recombinant B.t. strain EG7231, containing the cloned cryIIIC gene from B.t. strain EG4961 and described in Example 7, were grown on liquid sporulation medium and concentrated via centrifugation as described generally in Examples 5 through 7. Both concentrates were bioassayed against SCRW larvae and CPB larvae on artificial diet using previously described techniques but with three doses instead of eight and (for CPB) 16 CPB larvae per dose instead of 32. The results set forth in Table 5 demonstrate that B.t. strain EG7231 produces a CryIIIC crystal protein equal in toxicity to that found in B.t. strain EG4961. The crystal negative, sporulating B.t. strain EG7211 used to create B.t. strain EG7231 was tested as an additional control and was not active. This bioassay verifies that the cryIIIC gene produces the coleopteran-active crystal protein in B.t. strain EG4961.

Table 5

Activity of B.t. strains EG7231 and EG4961 against SCRW larvae and CPB larvae in artificial diet bioassays

25

LC₅₀ ng CryIII/mm² (95% C.I.)

Strain	SCRW	CPB
EG7231	359 (238-593)	0.23 (0.05-0.49)
EG4961	421 (253-1086)	0.32 (0.19-0.50)
EG7211	9.4% dead	12.5% dead
Control	6.25% dead	3.125 % dead

30

- 59 -

The following Example 13 relates to studies in which the insecticidal activity of CryIII proteins against coleopteran insects is demonstrably enhanced by the combination of a CryI protein with a CryIII protein. CryIA(c) protein crystals are not toxic to coleopteran insects, but are known to be active against numerous species of lepidopteran insects.

Example 13

10 Synergistic Enhancement of Insecticidal Activity of CryIII Protein by Adding CryI Protein

A recombinant B.t. strain, EG1269, producing only CryIA(c) protein crystals, was grown on liquid sporulation media using the techniques described above generally in Examples 5-7.

15 Recombinant B.t. strain EG1269 was constructed by introducing plasmid pEG157 into B.t. strain HD73-26. Plasmid pEG157 was made by subcloning the cryIA(c) gene from pEG87 (B.t. strain HD263-6),

20 into the shuttle vector pEG147. The CryIA(c) protein crystals were purified by Renografin gradient and quantified using the SDS-PAGE method mentioned previously. An equal amount of these CryI crystals was added to CryIIIC crystals and the

25 crystal protein mixture was bioassayed on artificial diet against SCRW larvae. The CryIIIC-CryI protein mixture was significantly more toxic than the CryIIIC crystals alone, as is clearly indicated by the data in Table 6.

- 60 -

Table 6

Insecticidal activity of a mixture of
CryIIIC and CryIA(c) crystal proteins against
SCRW larvae in an artificial diet bioassay

5	Treatment	# assays	LC ₅₀	ng CryIIIC/mm ²	(95% C.I.)
	CryIIIC crystals	2		1180	(810-2000)
	CryIIIC crystals + CryIA(c) crystals	2		309	(220-500)
10	CryIA(c) crystals	2		15.6% dead at 571 ng/mm ²	
	<u>Control mortality</u>			6.25%	

To assure the availability of materials to those interested members of the public upon issuance of a patent on the present application

15 deposits of the following microorganisms were made prior to the filing of present application with the ARS Patent Collection, Agricultural Research Culture Collection, Northern Regional Research Laboratory (NRRL), 1815 North University Street,

20 Peoria, Illinois 61064, as indicated in the following Table 7:

- 61 -

Table 7

	<u>Bacterial Strain</u>	<u>NRRL Accession No.</u>	<u>Date of Deposit</u>
	<u>B.thuringiensis</u> EG2158	B-18213	April 29, 1987
	<u>B.thuringiensis</u> HD73-26	B-18508	June 12, 1989
5	<u>B.thuringiensis</u> EG4961	B-18533	September 13, 1989
	<u>B.thuringiensis</u> EG2838	B-18603	February 8, 1990
	<u>B.thuringiensis</u> EG7231	B-18627	February 28, 1990
	<u>E. coli</u> EG7218	B-18534	September 13, 1989

10 These microorganism deposits were made
under the provisions of the "Budapest Treaty on the
International Recognition of the Deposit of
Microorganisms for the Purposes of Patent
Procedure". All restrictions on the availability
15 to the public of these deposited microorganisms
will be irrevocably removed upon issuance of a
United States patent based on this application.

20 The present invention may be embodied in
other specific forms without departing from the
spirit or essential attributes thereof and,
accordingly, reference should be made to the
appended claims, rather than to the foregoing
specification as indicating the scope of the
invention.

ANNEX M3

International Application No: PCT/

/

MICROORGANISMSOptional Sheet in connection with the microorganism referred to on page 4, line 27 of the description ¹**A. IDENTIFICATION OF DEPOSIT ¹**Further deposits are identified on an additional sheet ☒ ²Name of depository institution ³

American Research Culture Collection (NRRL)

Address of depository institution (including postal code and country) ⁴1815 N. University Street
Peoria, Illinois 61604 United States of AmericaDate of deposit ⁵

See Attachment

Accession Number ⁶

See Attachment

B. ADDITIONAL INDICATIONS ⁷ (leave blank if not applicable). This information is continued on a separate attached sheet ☐

In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)

C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE ⁸ (if the indications are not for all designated States)**D. SEPARATE FURNISHING OF INDICATIONS ⁹** (leave blank if not applicable)The indications listed below will be submitted to the International Bureau later ¹⁰ (Specify the general nature of the indications e.g., "Accession Number of Deposit")**E. ☒** This sheet was received with the international application when filed, to be checked by the receiving Office ¹¹

Nathaniel H. Hayden
PCT INTERNATIONAL SERVICES DIVISION
(Authorized Officer)

☐ The date of receipt (from the applicant) by the International Bureau ¹²

was

(Authorized Officer)

ATTACHMENT TO FORM PCT/RO/134

CONTINUATION OF "MICROORGANISM" BOX:

page 8, line 8
page 9, line 28
page 12, lines 6 and 8
page 42, line 5

CONTINUATION OF IDENTIFICATION OF DEPOSIT BOX A:

The following microorganisms were deposited in the depository institution listed in Box A on the dates listed below:

<u>Bacterial Strain</u>	<u>NRRL Accession No.</u>	<u>Date of Deposit</u>
<u>B.thuringiensis</u> EG2158	B-18213	April 29, 1987
<u>B.thuringiensis</u> HD73-26	B-18508	June 12, 1989
<u>B.thuringiensis</u> EG4961	B-18533	September 13, 1989
<u>B.thuringiensis</u> EG2838	B-18603	February 8, 1990
<u>B.thuringiensis</u> EG7231	B-18627	February 28, 1990
<u>E. coli</u> EG7218	B-18534	September 13, 1989
** <u>B.thuringiensis</u> EG7231	B-18627N	April 17, 1990

** Please note that the NRRL's sample of original deposit of B-18627 was found not to be equivalent to what was originally deposited by Ecogen Inc. As a result, a new deposit of the same microorganism, designated by Ecogen Inc. as EG7231, was sent to NRRL as a new deposit and given the accession number B-18627N.

CLAIMS

1. A purified and isolated cryIIIC gene having a nucleotide base sequence coding for the amino acid sequence illustrated in Figure 1.
2. A purified and isolated cryIIIC gene according to claim 1 wherein the gene has a coding region extending from nucleotide bases 14 to 1972 in the nucleotide base sequence illustrated in Figure 1.
3. A recombinant plasmid containing the gene of claim 1 or 2.
4. A coleopteran-toxic protein produced by the gene of claim 1 or 2.
5. A biologically pure culture of a bacterium transformed with the recombinant plasmid of claim 3.
6. The bacterium of claim 5 wherein the bacterium is Bacillus thuringiensis.
7. The Bacillus thuringiensis bacterium of claim 6 deposited with the NRRL having accession number NRRL B-18627.
8. An insecticide composition comprising the protein of claim 4 and an agriculturally acceptable carrier.

9. An insecticide composition comprising the bacterium of claim 5, a coleopteran-toxic protein produced by such bacterium, and an agriculturally acceptable carrier.

10. A plant transformed with the gene of claims 1 or 2.

11. The cryIIIC gene of claim 2 wherein the gene or a portion thereof is labeled for use as a hybridization probe.

12. A biologically pure culture of a Bacillus thuringiensis bacterium deposited with the NRRL having accession number NRRL B-18533.

13. A coleopteran-toxic protein characteristic of that made by the Bacillus thuringiensis bacterium of claim 12 and having the amino acid sequence illustrated in Figure 1.

14. An insecticide composition comprising the coleopteran-toxic protein of claim 13, in combination with an agriculturally acceptable carrier.

15. The insecticide composition of claim 14 wherein the coleopteran-toxic protein is contained in a Bacillus thuringiensis bacterium.

16. A method of controlling coleopteran insects comprising applying to a host plant for such insects an insecticidally effective amount of the coleopteran-toxic protein of claim 4.

17. The method of claim 16 wherein the coleopteran-toxic protein is contained in a Bacillus thuringiensis bacterium.

18. The method according to claim 16 wherein the insects are of the genus Diabrotica.

19. A method of controlling coleopteran insects which comprises applying to a host plant for such insects an insecticidally effective amount of the coleopteran-toxic protein of claim 13.

20. The method of claim 19 wherein the coleopteran-toxic protein is contained in a Bacillus thuringiensis bacterium.

21. The method of claim 19 wherein the insects are of the genus Diabrotica.

22. A method of enhancing the insecticidal activity of an insecticidal composition containing a coleopteran-toxic protein comprising incorporating into an insecticidal composition containing CryIII protein an amount of CryI protein effective to enhance the insecticidal activity of the composition against coleopteran insects.

23. The method according to claim 22 wherein the CryIII protein is CryIIIC protein.

24. The method according to claim 23 wherein the CryI protein is CryIA protein.

5 25. The method according to claim 23 wherein the CryI protein is CryIA(c) protein.

26. The method according to claim 22 wherein the CryIII protein and the CryI protein are present in approximately equal amounts.

10 27. The method according to any of claims 22 through 26 wherein the composition has enhanced insecticidal activity against insects of the genus Diabrotica.

15 28. An insecticide composition useful against coleopteran insects comprising the coleopteran-toxic protein of claim 13 and a CryI protein, the CryI protein being present in an amount effective to enhance the insecticidal activity of the composition against coleopteran
20 insects.

29. The composition of claim 28 wherein the CryI protein is CryIA protein.

30. The composition of claim 28 wherein the CryI protein is CryIA(c) protein.

31. The composition of claim 28 wherein the coleopteran-toxic protein and CryI protein are present in approximately equal amounts.

1/8

FIGURE 1A

```

      10      20      30      40      50      60
GGGAGGAAGAAAAATGAATCCAAACAATCGAAGTGAACATGATACGATAAAGGTTACACC
  RBS      MetAsnProAsnAsnArgSerGluHisAspThrIleLysValThrPr
      70      80      90     100     110     120
TAACAGTGAATTGCAAACCTAACCATATCAATATCCTTTAGCTGACAATCCAAATTC AAC
oAsnSerGluLeuGlnThrAsnHisAsnGlnTyrProLeuAlaAspAsnProAsnSerTh
      130     140     150     160     170     180
ACTAGAAGAATTAAATTATAAAGAATTTTAAAGAATGACTGAAGACAGTTCTACGGAAGT
rLeuGluGluLeuAsnTyrLysGluPheLeuArgMetThrGluAspSerSerThrGluVa
      190     200     210     220     230     240
GCTAGACAACCTCTACAGTAAAAGATGCAGTTGGGACAGGAATTTCTGTTGTAGGGCAGAT
lLeuAspAsnSerThrValLysAspAlaValGlyThrGlyIleSerValValGlyGlnIl
      250     260     270     280     290     300
TTTAGGTGTTGTAGGAGTTCCATTTGCTGGGGCACTCACTTCATTTTATCAATCATTCT
eLeuGlyValValGlyValProPheAlaGlyAlaLeuThrSerPheTyrGlnSerPheLe
      310     320     330     340     350     360
TAACACTATATGGCCAAGTGATGCTGACCCATGGAAGGCTTTTATGGCACAAGTTGAAGT
uAsnThrIleTrpProSerAspAlaAspProTrpLysAlaPheMetAlaGlnValGluVa
      370     380     390     400     410     420
ACTGATAGATAAGAAAATAGAGGAGTATGCTAAAAGTAAAGCTCTTGCAGAGTTACAGGG
lLeuIleAspLysLysIleGluGluTyrAlaLysSerLysAlaLeuAlaGluLeuGlnGl
      430     440     450     460     470     480
TCTTCAAAATAATTTTCGAAGATTATGTTAATGCGTTAAATTCCTGGAAGAAAACACCTTT
yLeuGlnAsnAsnPheGluAspTyrValAsnAlaLeuAsnSerTrpLysLysThrProLe
      490     500     510     520     530     540
AAGTTTGCGAAGTAAAAGAAGCCAAGATCGAATAAGGGAACTTTTTCTCAAGCAGAAAG
uSerLeuArgSerLysArgSerGlnAspArgIleArgGluLeuPheSerGlnAlaGluSe
      550     560     570     580     590     600
TCATTTTCGTAATTCATGCGTCATTTGCAGTTTCCAAATTCGAAGTGCTGTTTCTACC
rHisPheArgAsnSerMetProSerPheAlaValSerLysPheGluValLeuPheLeuPr
      610     620     630     640     650     660
AACATATGCACAAGCTGCAAATACACATTTATTGCTATTAAAGATGCTCAAGTTTTTTGG
oThrTyrAlaGlnAlaAlaAsnThrHisLeuLeuLeuLeuLysAspAlaGlnValPheGl
      670     680     690     700     710     720
AGAAGAATGGGGATATTCTTCAGAAGATGTTGCTGAATTTTATCATAGACAATTAAACT
yGluGluTrpGlyTyrSerSerGluAspValAlaGluPheTyrHisArgGlnLeuLysLe
      730     740     750     760     770     780
TACACAACAATACACTGACCATTGTGTTAATTGGTATAATGTTGGATTAAATGGTTTAAG
uThrGlnGlnTyrThrAspHisCysValAsnTrpTyrAsnValGlyLeuAsnGlyLeuAr
      790     800     810     820     830     840
AGGTTCAACTTATGATGCATGGGTCAAATTTAACCCTTTTCGCAGAGAAATGACTTTAAC
gGlySerThrTyrAspAlaTrpValLysPheAsnArgPheArgArgGluMetThrLeuTh
      850     860     870     880     890     900
TGTATTAGATCTAATTGTACTTTTCCCATTTTATGATATTCGGTTATACTCAAAGGGGT
rValLeuAspLeuIleValLeuPheProPheTyrAspIleArgLeuTyrSerLysGlyVa

```

2/8

FIGURE 1B

910 920 930 940 950 960
 TAAACAGAACTAACAAGAGACATTTTACGGATCCAATTTTTCACCTAATACTCTTCA
 lLysThrGluLeuThrArgAspIlePheThrAspProIlePheSerLeuAsnThrLeuGl
 970 980 990 1000 1010 1020
 GGAGTATGGACCAACTTTTTTGAGTATAGAAAACCTCTATTCGAAAACCTCATTATTGGA
 nGluTyrGlyProThrPheLeuSerIleGluAsnSerIleArgLysProHisLeuPheAs
 1030 1040 1050 1060 1070 1080
 TTATTACAGGGGATTGAATTTTCATACGCGTCTTCAACCTGGTTACTTTGGGAAAGATTC
 pTyrLeuGlnGlyIleGluPheHisThrArgLeuGlnProGlyTyrPheGlyLysAspSe
 1090 1100 1110 1120 1130 1140
 TTTCAATTATTGGTCTGGTAATTATGTAGAACTAGACCTAGTATAGGATCTAGTAAGAC
 rPheAsnTyrTrpSerGlyAsnTyrValGluThrArgProSerIleGlySerSerLysTh
 1150 1160 1170 1180 1190 1200
 AATTACTTCCCCATTTTATGGAGATAAATCTACTGAACCTGTACAAAAGCTAAGCTTTGA
 rIleThrSerProPheTyrGlyAspLysSerThrGluProValGlnLysLeuSerPheAs
 1210 1220 1230 1240 1250 1260
 TGGACAAAAAGTTTATCGAACTATAGCTAATACAGACGTAGCGGCTTGGCCGAATGGTAA
 pGlyGlnLysValTyrArgThrIleAlaAsnThrAspValAlaAlaTrpProAsnGlyLy
 1270 1280 1290 1300 1310 1320
 GGTATATTTAGGTGTTACGAAAGTTGATTTTAGTCAATATGATGATCAAAAAAATGAAAC
 sValTyrLeuGlyValThrLysValAspPheSerGlnTyrAspAspGlnLysAsnGluTh
 1330 1340 1350 1360 1370 1380
 TAGTACACAAACATATGATTCAAAAAGAAACAATGGCCATGTAAGTGCACAGGATTCTAT
 rSerThrGlnThrTyrAspSerLysArgAsnAsnGlyHisValSerAlaGlnAspSerIl
 1390 1400 1410 1420 1430 1440
 TGACCAATTACCGCCAGAAACAACAGATGAACCACTTGAAAAAGCATATAGTCATCAGCT
 eAspGlnLeuProProGluThrThrAspGluProLeuGluLysAlaTyrSerHisGlnLe
 1450 1460 1470 1480 1490 1500
 TAATTACGCGGAATGTTTCTTAATGCAGGACCGTCGTGGAACAATTCATTTTTTACTTG
 uAsnTyrAlaGluCysPheLeuMetGlnAspArgArgGlyThrIleProPhePheThrTr
 1510 1520 1530 1540 1550 1560
 GACACATAGAAGTGTAGACTTTTTTAATACAATTGATGCTGAAAAGATTACTCAACTTCC
 pThrHisArgSerValAspPhePheAsnThrIleAspAlaGluLysIleThrGlnLeuPr
 1570 1580 1590 1600 1610 1620
 AGTAGTGAAAGCATATGCCTTGTCTTCAGGTGCTTCCATTATTGAAGGTCCAGGATTAC
 oValValLysAlaTyrAlaLeuSerSerGlyAlaSerIleIleGluGlyProGlyPheTh
 1630 1640 1650 1660 1670 1680
 AGGAGGAAATTTACTATTCTCTAAAGAATCTAGTAATTCAATTGCTAAATTTAAAGTTAC
 rGlyGlyAsnLeuLeuPheLeuLysGluSerSerAsnSerIleAlaLysPheLysValTh
 1690 1700 1710 1720 1730 1740
 ATTAAATTCAGCAGCCTTGTTACAACGATATCGTGTAAGAATACGCTATGCTTCTACCAC
 rLeuAsnS rAlaAlaLeuLeuGlnArgTyrArgValArgIleArgTyrAlaSerThrTh
 1750 1760 1770 1780 1790 1800
 TAACTTACGACTTTTTGTGCAAAATTCAAACAATGATTTTCTTGTCATCTACATTAATAA
 rAsnLeuArgLeuPheValGlnAsnSerAsnAsnAspPheLeuValIleTyrIleAsnLy

3/8

FIGURE 1c

1810	1820	1830	1840	1850	1860
A ¹ CTATGAATAAAGATGATGATTTAACATATCAAACATTTGATCTCGCAACTACTAATTC					
sThrMetAsnLysAspAspAspLeuThrTyrGlnThrPheAspLeuAlaThrThrAsnSe					
1870	1880	1890	1900	1910	1920
TAATATGGGGTTCTCGGGTGATAAGAATGAACTTATAATAGGAGCAGAATCTTTCGTTTC					
rAsnMetGlyPheSerGlyAspLysAsnGluLeuIleIleGlyAlaGluSerPheValSe					
1930	1940	1950	1960	1970	
TAATGAAAAAATCTATATAGATAAGATAGAATTTATCCCAGTACAATTGTAA					
rAsnGluLysIleTyrIleAspLysIleGluPheIleProValGlnLeuEnd					

SUBSTITUTE SHEET

4/8




FIG. 2




FIG. 3

SUBSTITUTE SHEET

5/8




FIG. 4




FIG. 5

SUBSTITUTE SHEET

6/8




FIG. 6

SUBSTITUTE SHEET




FIG. 7




FIG. 8




FIG. 9

8/8




FIG. 10

SUBSTITUTE SHEET